BiomX Inc
For the period ended Dec 31, 2023. Filed Apr 4, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 4, 2024
HLSQ$0.11-13.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Year ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Research and development (“R&D”) expenses, net | 16,698 | 16,244 |
| Amortization of intangible assets | - | 1,519 |
| General and administrative expenses | 8,650 | 9,456 |
| Operating loss | 25,348 | 27,219 |
| Other income | (357) | (134) |
| Interest expenses | 2,404 | 2,069 |
| Finance income, net | (1,249) | (902) |
| Loss before tax | 26,146 | 28,252 |
| Tax expenses | 23 | 65 |
| Net Loss | 26,169 | 28,317 |
| Basic and diluted loss per share of Common Stock | 0.51 | 0.95 |
| Weighted average number of shares of Common Stock outstanding, basic and diluted | 51,330,324 | 29,854,003 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.